Does Ozempic actually damage your liver? Here's what the data shows

What did @weightdoc actually say?

@weightdoc summarized results from the ESSENCE trial, a Phase 3 study published in the New England Journal of Medicine, testing semaglutide in people with MASH (Metabolic Dysfunction-Associated Steatohepatitis). The claim: 62% of people on semaglutide had "complete resolution" of MASH versus 34% on placebo, and 36% showed improved fibrosis versus 22% on placebo. They also gave a decent explainer on what MASH is, how it differs from basic fatty liver disease, and why weight loss is the primary treatment. The numbers cited are largely accurate. The framing is mostly responsible. That said, there are some details worth pushing back on.

Does the science back this up?

Mostly, yes. The ESSENCE trial (Loomba et al., 2025, New England Journal of Medicine) was a well-designed, double-blind, placebo-controlled Phase 3 trial involving 800 patients across 37 countries. The semaglutide dose used was 2.4 mg weekly, the same dose approved under the brand name Wegovy for weight management. The histological resolution numbers @weightdoc cited are accurate and directly match the published primary endpoints. The fibrosis improvement numbers are also correct. What the creator skips is that semaglutide's FDA approval for MASH had not been granted at the time of publication, meaning this is promising trial data, not an approved indication. That distinction matters when millions of people are watching a TikTok and might assume their Ozempic prescription already covers this.

What did they get wrong (or right)?

The biggest error is a drug name issue. The creator repeatedly says "some Agletide" which is clearly a mangled pronunciation of semaglutide. That is a transcription artifact, probably from speech-to-mouth error, but it muddies the message for viewers trying to look this up. The broader framing is actually solid. The creator correctly explains that MASH was renamed from NASH to reflect metabolic origins, which happened in 2023 (Rinella et al., 2023, Hepatology). They are right that fatty liver disease affects roughly 30% of Americans, which aligns with NHANES-based prevalence estimates. The 5% MASH prevalence figure is a reasonable population estimate. One soft overclaim: saying weight loss is the "primary treatment" is accurate but incomplete. Resmetirom (Rezdiffra) was FDA-approved for MASH in March 2024, meaning there is now a dedicated pharmacological option, which goes unmentioned. Omitting that context makes semaglutide sound more like the only option than it is.

What should you actually know?

MASH is a serious disease with limited treatment options until recently, and the ESSENCE trial results are genuinely significant. But a few things need clarifying before anyone takes this TikTok to their doctor. First, the semaglutide used in this trial was 2.4 mg weekly. Standard Ozempic doses for diabetes top out at 2 mg weekly. These are not the same thing in clinical practice. Second, semaglutide is not FDA-approved to treat MASH as of early 2025. Using it off-label for liver disease is a conversation to have with a physician, not a decision to make based on a viral video. Third, the placebo group also showed meaningful improvement (34% resolution), which tells you that metabolic lifestyle changes, trial participation effects, and regression to the mean all play roles. The drug effect is real, but it does not operate in a vacuum.

Bottom line

This is one of the more accurate GLP-1 videos circulating right now. @weightdoc got the trial numbers right, explained the disease rename correctly, and avoided overpromising. The gaps are meaningful though: no mention of resmetirom as an approved MASH treatment, no clarification that Ozempic and Wegovy use different doses, and no acknowledgment that this remains an unapproved indication. For a 1.8 million view video, those omissions matter. The science here is real and worth knowing. Just do not walk away thinking your Ozempic prescription is already treating your liver.